Skye Bioscience to discontinue development of eye disease treatment
June 10 (Reuters) - Skye Bioscience SKYE.O said on Monday it intends to discontinue development of its experimental eye disease treatment after it failed in a mid-stage study. (Reporting by Sneha S K in Bengaluru; Editing by Krishna Chandra Eluri) ((Sneha.SK@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsRCS - Redx Pharma Limited - Redx to Present Poster on RXC008 at UEG Week
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
Brief: Skye Bioscience Says John Sharp Resigns As CFO - SEC Filing
Brief: Skye Bioscience - Enters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments Iii - SEC Filing
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM